1	
2	
2	
3	
4	
5	
6	
7	
8	
9	Retrospective in silico HLA predictions from COVID-19 patients
10	reveal alleles associated with disease prognosis
10	reveal alleles associated with disease prognosis
11	
12	
13	Rene L. Warren and Inanç Birol
14	
15	
10 17	
18	
10	
20	René I. Warren
20	Genome Sciences Centre BC Cancer
22	Vancouver, BC, V5Z 4S6, Canada
23	rwarren@bcgsc.ca
24	570 W 7th Ave #100, Vancouver, BC V5Z 4S6
25	(604) 707-5900 #673235
26	
27	*To whom correspondence should be addressed
28	
29	
30	Inanç Birol
31	Genome Sciences Centre, BC Cancer
32	Vancouver, BC, V5Z 4S6, Canada
33	<u>ibirol@bcgsc.ca</u>
34 25	
35	
36	
37	
38	

39 ABSTRACT

40 **Background:** The Human Leukocyte Antigen (HLA) gene locus plays a fundamental

41 role in human immunity, and it is established that certain HLA alleles are disease

42 determinants.

43 **Methods:** By combining the predictive power of multiple *in silico* HLA predictors, we

44 have previously identified prevalent HLA class I and class II alleles, including

45 DPA1*02:02, in two small cohorts at the COVID-19 pandemic onset. Since then, newer

46 and larger patient cohorts with controls and associated demographic and clinical data

47 have been deposited in public repositories. Here, we report on HLA-I and HLA-II alleles,

48 along with their associated risk significance in one such cohort of 126 patients, including

49 COVID-19 positive (n=100) and negative patients (n=26).

50 **Results:** We recapitulate an enrichment of DPA1*02:02 in the COVID-19 positive

51 cohort (29%) when compared to the COVID-negative control group (Fisher's exact test

52 [FET] p=0.0174). Having this allele, however, does not appear to put this cohort's

53 patients at an increased risk of hospitalization. Inspection of COVID-19 disease severity

54 outcomes reveal nominally significant risk associations with A*11:01 (FET p=0.0078),

55 C*04:01 (FET p=0.0087) and DQA1*01:02 (FET p=0.0121).

56 Conclusions: While enrichment of these alleles falls below statistical significance after 57 Bonferroni correction, COVID-19 patients with the latter three alleles tend to fare worse 58 overall. This is especially evident for patients with C*04:01, where disease prognosis 59 measured by mechanical ventilation-free days was statistically significant after multiple

60 hypothesis correction (Bonferroni p = 0.0023), and may hold potential clinical value.

- 61 Keywords (8): COVID-19, SARS-CoV-2, Human Leukocyte Antigen (HLA), RNA-seq,
- 62 DPA1*02:02, A*11:01, C*04:01, DQA1*01:02

63 INTRODUCTION

64

Modern history has been plaqued by deadly outbreaks, from the recurring influenza 65 66 (e.g. Spanish, Asian, Hong Kong, Avian) and HIV/AIDS viral pandemics, to bacterial 67 and protist infections causing tuberculosis and malaria. Since the early 2000s, we have 68 faced another threat: novel coronavirus infections causing severe respiratory illnesses 69 such as SARS, MERS and today, coronavirus disease 2019 – COVID-19 [1]. The 70 SARS-CoV-2 coronavirus responsible for the COVID-19 respiratory disease is of 71 particular concern; not only does SARS-CoV-2 spread quickly, the symptoms of its 72 infection, when exhibited, are very similar to that of the cold and flu making it difficult to 73 diagnose, trace and contain. Further, infected individuals are affected differently. For 74 instance, older men (\geq 65 years old) with pre-existing medical conditions, such as 75 diabetes, appear at increased risk of progressing into the more severe phase of the 76 disease, yet SARS-CoV-2 infections affect all other age groups evenly except 77 occasionally in children and adolescents [2]. Most peculiar is that a high proportion of 78 individuals who tested positive for SARS-CoV-2 are asymptomatic – as high as 43% 79 recorded in Iceland, a rate that appears to vary depending on jurisdictions and 80 populations [3-5]. As of now, the disparity in patient response to SARS-CoV-2 infection 81 is still eluding us. 82 The most efficient way to combat pathogens has been through the use of our

82 The most efficient way to combat pathogens has been through the use of our
 83 own defense mechanism: our acquired immunity. This is done by vaccination
 84 campaigns that effectively prime our immune systems at the population level before we
 85 even encounter pathogens. But design of effective vaccines must consider interactions

86 with host immune genes. The Human Leukocyte Antigens (HLA) are a group of such 87 genes encoding surface receptors that bind short peptide epitopes derived from 88 endogenous (class I) or exogenous (class II) antigens, including viral antigens, and they 89 facilitate killer or helper T cells to set off an appropriate immune response. The 90 magnitude of this response varies between patients as populations and individuals have 91 different composition of HLA genes and variable T cell repertoires. As such, HLA 92 induces a bias, which is responsible for documented host susceptibility to disease [6]. 93 Some of the notable associations between HLA and disease are observed in AIDS 94 patients, with certain HLA alleles conferring protection [7]. In other cases, HLA has been 95 implicated with autoimmune diseases and diabetes [8-11]. The exact underlying 96 mechanisms behind these associations are unclear, but there is mounting evidence that 97 bacterial and viral infection may be the trigger for some [10] and that HLA plays a critical 98 role in the viral infection cycle, including viral entry into host cells [12]. 99 Since the beginning of the pandemic, worldwide reports have emerged on HLA 100 associations with COVID-19, including our own [13-19]. Using publicly available 101 metatranscriptomic sequencing data made available at the pandemic onset, we had 102 demonstrated the utility of a high throughput in silico method for characterizing the HLA 103 types of COVID-19 patients from bronchoalveolar lavage fluid and blood samples and 104 reported on prevalent alleles, including the DPA1*02:02P - DPB1*05:01P HLA-II 105 haplotype observed in 7 out of the 8 of patients from two small cohorts. Here, using 106 public RNA-seq sequencing data from a larger COVID-19 patient cohort with clinical 107 outcomes and demographics data [20], we report on HLA alleles with potential 108 diagnostic (DPA1*02:02) and prognostic (A*11:01, C*04:01 and DQA1*01:02) value in

- 109 126 hospitalized patients with (n=100) and without (n=26) COVID-19 and present our
- 110 findings in light of available demographic characteristics using hospitalization and
- 111 disease severity metrics.

112 **METHODS**

114	We downloaded Illumina NOVASEQ-6000 paired-end (50 bp) RNA-Seq reads from
115	libraries prepared from the blood samples of 126 hospitalized patients, with (n=100) or
116	without COVID-19 (n=26) (ENA project: PRJNA660067, accessions: SRX9033799-
117	SRX9033924). This data is part of a large-scale multi omics study from the Department
118	of Molecular and Cellular Physiology, Albany Medical College, Albany, NY, USA, with
119	aims to analyze COVID-19 Severity and clinical as well as demographics data was
120	made available by the study authors [20] (GEO accession GSE157103). On each
121	patient RNA-Seq dataset, we ran HLA prediction software OptiType [21] (v1.3.4),
122	seq2HLA [22] (v2.3), and HLAminer [23] (v1.4 targeted assembly mode with defaults)
123	as described [19]. We tallied HLA class I (HLA-I) and class II (HLA-II, supported by
124	Seq2HLA and HLAminer only) allele predictions and for each patient we report the most
125	likely HLA allele (4-digit resolution), indicating HLA predictor tool support (Additional
126	file 1, tables S1 and S2).
127	Looking at class I and II alleles predicted in 10% or more of COVID-19 positive
128	patients (class I, n=17; class II, n=11) we calculated Fisher's Exact Test (FET), first
129	testing for enrichment in COVID-19 positive vs. negative patients (R function fisher.test,
130	alternative = "greater"). For those same alleles (found in \geq 10% patients) and inspecting
131	only the COVID-19 positive cohort, we tested for the probability of patient
132	hospitalization, as measured by the Intensive Care Unit (ICU) metric reported by the
133	original study authors, using FET. We looked further into the risk of hospitalization in
134	COVID-19 patients with vs. without these alleles using the Kaplan-Meier (KM) estimator
135	(R library survival), plotting the probability of remission using the "hospital-free days

136 post 45 day followup (days)" (HFD-45) metric reported by the study author as a proxy 137 for disease severity, with lower HFD-45 numbers indicating worse outcomes. Similarly, 138 we ran the KM estimator using another metric of disease severity, "ventilator-free days". 139 which captures the most severe cases with COVID-19 patients suffering respiratory 140 deterioration and requiring mechanical ventilation. On each set we calculated the log-141 rank p-value (R library survminer) and corrected for multiple hypothesis testing 142 (Bonferroni correction) using the number and patient abundance rank of class I (n=17) 143 or class II (n=11) HLA alleles observed in 10% or more of COVID-19 patients. We also 144 inspected the combined influence of HLA alleles and patient demographics data (age, 145 sex, ethnicity) on the hospitalization (ICU negative vs. positive) outcomes of COVID-19 146 patients, using odds-ratio calculations (R function fisher.test, and applying Haldane 147 correction [24] on zero values, when necessary).

148**RESULTS**

149

150 We collated the HLA class I and class II predictions of three *in silico* HLA predictors 151 derived from the RNA-seq samples of a recent [20] COVID-19 positive patient cohort 152 (n=100) with control patients (n=26) who tested negative for COVID-19 (Additional file 153 **1, Tables S1 and S2**). Due to the limiting short read length (paired 50 bp) we chose to 154 first report on OptiType [21] and seq2HLA [22] class I and class II predictions, and count 155 the additional allele support from seq2HLA and HLAminer [23]. In all, we identify 17 and 156 11 HLA class I and class II alleles predicted in 10% or more of COVID-19 patients, 157 respectively (Tables 1 and 2). There were many more alleles predicted (133 class I and 158 101 class II in the COVID-19 positive cohort), but too few patients are represented at 159 lower cut-offs to compute meaningful statistics. First, we looked at the statistical 160 enrichment (Fisher's Exact Test - FET) of each allele in the COVID-19 positive set, 161 compared to the COVID-19 negative control group. We find HLA-I A*30:02 and HLA-II 162 DPA1*02:02 allele enrichments nominally significant (FET p = 0.0417 and p = 0.0174) 163 at the 5% level (Tables 1 and 2). However, when Bonferroni correction is applied for 164 the number of HLA class I allele tests or when the abundance rank is factored in for 165 A*30:02, the test is not significant (n=17, Bonferroni p = 0.7080; n=10, Bonferroni p =166 0.4165, respectively). For HLA-II DPA1*02:02, Bonferroni correction finds the test 167 insignificant at the α =0.05 level for the number of hypothesis, but significant for the 168 allele abundance rank (n=11, Bonferroni p = 0.1916; n=2, Bonferroni p = 0.0348). 169 COVID-19 positive patients could be further stratified into those who were 170 hospitalized and admitted to the Intensive Care Unit (Tables I and 2, ICU+), and those 171 who were not (Tables 1 and 2, ICU-). When computing FET statistics, we find HLA-I

172 A*11:01 and C*04:01 and HLA-II DQA1*01:02 significant at the α =0.05 level (**Tables 1** 173 and 2; p = 0.0078, p = 0.0087 and 0.0121, respectively) but none remain significant 174 after Bonferroni correction. The Overmyer study authors [20] reported important disease 175 severity metrics (HFD-45 and days without needing mechanical ventilation), which we 176 used to assess the remission probability of COVID-19 patients having a specific allele 177 using Kaplan-Meier estimation. We find patients of the Overmyer cohort with either 178 A*11:01 (Figure1a), C*04:01 (Figure 1b) or DQA1*01:02 (Figure 1c) to be at a 179 significant increased risk of hospitalization (log-rank p = 0.0099, p = 0.0082 and p =180 0.0097). When applying multiple test corrections to account for allele abundance rank, 181 only C*04:01 (n=5, Bonferroni p = 0.0410) and DQA1*01:02 (n=2, Bonferroni p =182 0.0194) remained significant at the α =0.05 level. When looking at patients needing 183 mechanical ventilators, a severe outcome in COVID-19 disease progression, we only 184 find patients with C*04:01 to be at a statistically significant increased risk (Figure 1d, 185 log-rank p = 0.0019). Multiple hypothesis test correction retains the statistical 186 significance of this allele when factoring both the number of HLA-I alleles tested and 187 C*04:01 abundance rank (n=17, Bonferroni p = 0.0023; n=5, Bonferroni p = 0.0095). 188 Looking at the influence of the aforementioned alleles in combination with simple 189 demographics (sex, age and ethnicity), we find that of the Overmyer cohort patients with 190 the DPA1*02:02 allele, those with a white ethnic background and females appear at an 191 increased risk of testing positive for COVID-19 (Figure 2; odds ratio [OR] = 6.33 [5.33-192 7.34], FET p = 0.0491 and OR = 7.33 [6.18-8.48], FET p = 0.0326, respectively). The 193 association with gender is also observed in alleles A*11:01, C*04:01 and DQA1:01:02, 194 putting female COVID-19 patients of this cohort at an increased risk of hospitalization

195	for the class I alleles (Figure 2; OR = $12.09 [10.41-13.76]$, FET p = 0.0105 for both) and
196	male COVID-19 patients at increased risk for DQA1*02:02 (Figure 2; OR = 2.74 [2.69-
197	2.79], FET $p = 0.0481$). For patients with the latter HLA-II allele, minorities and younger
198	individuals (<65 years old) are also more at risk of hospitalization (Figure 2; OR = 4.08
199	[2.85-5.32], FET p = 0.0222 and OR = 3.62 [2.42-4.83], FET p = 0.0240, respectively).
200	In this cohort, we also find patients with A*11:01 in the younger age group (<65 years
201	old) at increased risk of hospitalization (Figure 2 ; OR = 9.54 [8.14-10.94], FET p =
202	0.0184) whereas for those with C*04:01, it appears a white ethnic background and a
203	more advanced age (≥65 years old) may be predisposing to ICU hospitalization (Figure
204	2 ; OR = 14.25 [12.24-16.26], FET p = 0.0053 and OR = 9.66 [8.27-11.05], FET p =

205 0.0188, respectively).

206 **DISCUSSION**

207

208	We have previously identified the DPA1*02:02 class II allele as being prevalent in two
209	other and independent cohorts, with patients of undisclosed ethnic background, but
210	hospitalized in Wuhan, China [19]. Of populations with reported allele frequencies and
211	an appreciable sampling size (≥100 individuals), only Hong Kong Chinese and
212	Japanese have DPA1*02:02 allele frequencies (55.8% and 43.5%, respectively; [25,26])
213	above its observed frequency (29.0%) in the COVID-19 positive cohort analyzed herein.
214	The frequency of this allele in other qualifying populations tends to be generally lower,
215	including in South African (Worcester, 15.6%), Norwegians (14.0%), Mexico Chiapas
216	Lacandon Mayans (6.7%), United Kingdom Europeans (4.3%) and Spain Navarre
217	Basques (2.2%). We note that the ethnic background of the Overmyer et al [20] cohort
218	is heterogeneous, and white individuals (of unknown ancestry) represent 45.1% and
219	(11/29) 37.9% of the COVID-19 positive cohort and its DPA1*02:02 subset,
220	respectively. In contrast, Asians represent only a minority of the cohort (1.9%) and
221	DPA1*02:02 subset (1/29~3.4%). It is important to note that, in the Overmyer cohort,
222	DPA1*02:02 is not statistically associated with increased risk of hospitalization. The
223	significant enrichment of this allele in the COVID-19 positive vs. negative cohorts (FET
224	p=0.0174) across all individuals, but also when looking only at females (FET $p=0.0326$)
225	or white individuals (FET $p= 0.0491$), and not any other demographics, may prove an
226	important disease marker, which would need to be validated with additional datasets
227	and in independent studies.

There are reports of disease associations with DPA1*02:02, DQA1*01:02, 228 229 C*04:01 and A*11:01, but they are few. Of note, the association of all aforementioned 230 alleles with narcolepsy [10,11] and a known trigger for this auto-immune disease 231 includes upper-airway infections and influenza vaccinations [27-32]. Susceptibility to 232 narcolepsy may in fact be an indirect effect of HLA class I and the HLA class II DP 233 isotype in response to viral and bacterial infections, including from influenza and 234 streptococcus [10,27,33,34]. It has since been reported that HLA-A*11 may be a 235 susceptibility allele to influenza A(H1N1)pdm09 infection in some populations [35] while 236 another report implicates HLA-I allele C*04:01 with high HIV viral loads [36]. Further, it 237 was recently demonstrated that MHC class II DR, DQ and DP isotypes play a role in 238 mediating the cross-species entry of bat influenza viruses in vitro in human/animal cell 239 lines and in mice where engineered MHC-II deficiency made them resistant to upper-240 respiratory tract infections [12]. It is therefore not a stretch to envision an involvement 241 from these HLA class II isotypes in controlling the cellular entry of a broader range of 242 viral agents in vivo.

In a recent study examining HLA susceptibility based on SARS-CoV-2 derived peptide (epitope) binding strengths [37], the HLA-I allele A*11:01 was *in silico* predicted to bind a large number of SARS-CoV-2 derived peptides (n=750) with varying affinity [IC50 range 4.95 – 498.19, median = 149.62, mean = 182.28], and has been experimentally validated to bind SARS-CoV-2 peptide GLMWLSYFV (Tables S4 and S7 in Nguyen *et al.* [37]). In contrast, C*04:01 was only predicted *in silico* to bind six SARS-CoV-2 peptides and at higher IC50 ranges [167.65 – 469.30, median = 291.06, mean =

299.01] (Table S7 in Nguyen *et al.* [37]) suggesting a more limited ability to present
epitopes to T cells and mount an appropriate immune response.

252 There have been a number of reports published on HLA alleles – COVID-19 253 associations this past year, and on cohorts from many jurisdictions including China [18], 254 Italy [13,14,16] and the UK [17]. Wang et al. [18] compared the HLA allele frequencies 255 between a cohort of 82 Chinese individuals and a control population of bone marrow 256 donors previously studied by the same group. Novelli and co-workers [14] HLA typed a 257 cohort of 99 Italian COVID-19 patients, and associated the observed allele frequencies 258 with the HLA types in a reference group of 1,017 Italian individuals also previously 259 studied by the same group. Correale et al. [13] and Pisanti et al. [16] followed a different 260 strategy; these two independent studies leveraged population scale genomics data 261 retrieved from the Italian Bone-Marrow Donors Registry and the National Civil 262 Protection Department. They correlated background HLA allele frequency data with 263 mortality and morbidity rates across Italy to reach at starkly different conclusions on 264 which HLA alleles may play a role in disease etiology and progression. Disagreement 265 between these two studies (also distinct from the results of the other Italian study by 266 Novelli et al.) highlight the importance of large cohorts with matched samples to infer 267 the patient HLA alleles with better statistical significance. Poulton et al. [17] 268 characterized the HLA types of 80 COVID-19 patients in the UK on waiting lists for 269 transplantation, and compared observed allele frequencies in comparison to a cohort of 270 10,000 deceased organ donors and a separate cohort of 308 SARS-CoV-2-negative 271 individuals also on waiting lists for transplantation, the latter representing a matched 272 demographics for the COVID-19 patients in their cohort. Interestingly, this is the only

273 study that had any overlap between the alleles they flagged as being statistically 274 significant and the lists published by other studies cited above. Not surprisingly, the 275 alleles they listed do not intersect with the alleles identified and presented herein and 276 the three alleles we published earlier on a very small group of only eight patients. It is 277 nonetheless intriguing to find little to no HLA allele overlap between these reports, 278 including with those associated with the 2003 SARS outbreak, a related respiratory 279 disease caused by coronavirus [15,38,39]. This could be explained, at least partially, by 280 geographical differences and varying population allele frequencies in those cohorts, 281 relatively small cohort sizes (<100 patients), differences in experimentation setup and/or

other factors, including comorbidity status, that may be acting independently of HLA.

283 CONCLUSIONS

285	Here, we predict HLA-I and HLA-II alleles from publicly available COVID-19 patient
286	blood RNA-seq samples and identified several putative biomarkers. In a previous study,
287	we had observed one of these biomarkers (DPA1*02:02), and we postulate that patients
288	with the allele may have an increased susceptibility for COVID-19. Further, other alleles
289	(A*11:01, C*04:01, DQA1*01:02) may be prognostic indicators of poor outcome.
290	However, although it is well established that patient HLA profiles play a significant role
291	in the onset and progression of infectious diseases in general, we caution against
292	drawing overreaching conclusions from regional, and often limited, observations. We
293	note that recently published studies associating HLA alleles and COVID-19, by and
294	large, disagree in their findings. We expect future studies with larger cohort sizes will
295	help bring a clearer picture of the role of patient HLA profiles, if any, in COVID-19
296	susceptibility and disease outcomes.

297 LIST OF ABBREVIATIONS

298

- 300 FET: Fisher's Exact Test; HFD-45: hospital-free days post 45 day followup (days); HLA:
- 301 human leukocyte antigen; ICU: Intensive Care Unit; KM: Kaplan-Meier

302 **DECLARATIONS**

- 303
- 304

305 Ethics approval and consent to participate

- 306 Not applicable
- 307

308 Consent for publication

- 309 Not applicable
- 310

311 Availability of data and materials

- 312 The RNA-seq datasets analysed during the current study are available in the ENA
- 313 repository https://www.ebi.ac.uk/ena/browser/view/PRJNA660067 accessions:
- 314 SRX9033799- SRX9033924. The associated clinical data are available in the GEO
- 315 repository <u>https://www.ncbi.nlm.nih.gov/geo</u> accession: GSE157103
- 316

317 Competing interests

318 The authors declare that they have no competing interests

319320 Funding

- 321 This work was supported by Genome BC and Genome Canada [281ANV]; and
- 322 the National Institutes of Health [2R01HG007182-04A1]. The content of this
- 323 paper is solely the responsibility of the authors, and does not necessarily
- 324 represent the official views of the National Institutes of Health or other funding
- 325 organizations.
- 326

327 Authors' contributions

- 328 RLW designed the study, analyzed the data and wrote the manuscript. IB participated in
- 329 the development of the study and co-wrote the manuscript. All authors have read and
- approved the manuscript.
- 331

332 Acknowledgements

333 Not applicable

334 **REFERENCES**

335

- 1. Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, et al. Comparing
- 337 SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis.
- 338 2020;20:e238-e244.

339

- 2. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of
- Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708-20.

342

- 343 3. Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL,
- 344 et al. Spread of SARS-CoV-2 in the Icelandic Population. N Engl J Med.

345 2020;382:2302-15.

346

- 4. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic
- 348 proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond
- 349 Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020;25:2000180.

350

- 351 5. Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung SM, Hayashi K, et al. Estimation
- 352 of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis.
- 353 2020;94:154-5.

354

6. Dendrou CA, Petersen J, Rossjohn J, Fugger L. HLA variation and disease. Nat Rev
Immunol. 2018;18:325-39.

357	7. Goulder PJ, Walker BD. HIV and HLA class I: an evolving relationship. Immunity.
358	2012;37:426-40.

359

- 360 8. Chu X, Yang M, Song ZJ, Dong Y, Li C, Shen M, et al. Fine mapping MHC
- 361 associations in Graves' disease and its clinical subtypes in Han Chinese. J Med Genet.
- **2018;55:685-92**.

363

- 364 9. Noble JA, Valdes AM, Bugawan TL, Apple RJ, Thomson G, Erlich HA. The HLA class
- I A locus affects susceptibility to type 1 diabetes. Hum Immunol. 2002;63:657-64.

366

10. Ollila HM, Ravel JM, Han F, Faraco J, Lin L, Zheng X, et al. HLA-DPB1 and HLA

class I confer risk of and protection from narcolepsy. Am J Hum Genet. 2015;96:136-46.

369

11. Tafti M, Lammers GJ, Dauvilliers Y, Overeem S, Mayer G, Nowak J, et al.

371 Narcolepsy-Associated HLA Class I Alleles Implicate Cell-Mediated Cytotoxicity. Sleep.

2016;39:581-7.

373

12. Karakus U, Thamamongood T, Ciminski K, Ran W, Günther SC, Pohl MO, et al.

- 375 MHC class II proteins mediate cross-species entry of bat influenza viruses. Nature.
- **376 2019;567:109-12**.

378	13. Correale P, Mutti L, Pentimalli F, Baglio G, Saladino RE, Sileri P, Giordano A. HLA-
379	B*44 and C*01 Prevalence Correlates with Covid19 Spreading across Italy. Int J Mol
380	Sci. 2020;21:5205.
381	
382	14. Novelli A, Andreani M, Biancolella M, Liberatoscioli L, Passarelli C, Colona VL, et al.
383	HLA allele frequencies and susceptibility to COVID-19 in a group of 99 Italian patients.
384	HLA. 2020; doi:10.1111/tan.14047.
385	
386	15. Ovsyannikova IG, Haralambieva IH, Crooke SN, Poland GA, Kennedy RB. The role
387	of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility
388	and severity. Immunol Rev. 2020;296:205-19.
389	
390	16. Pisanti S, Deelen J, Gallina AM, Caputo M, Citro M, Abate M, et al. Correlation of
391	the two most frequent HLA haplotypes in the Italian population to the differential
392	regional incidence of Covid-19. J Transl Med. 2020;18:352.
393	
394	17. Poulton K, Wright P, Hughes P, Savic S, Welberry Smith M, Guiver M, et al. A role
395	for human leucocyte antigens in the susceptibility to SARS-Cov-2 infection observed in
396	transplant patients. Int J Immunogenet. 2020;47:324-8.
397	
398	18. Wang W, Zhang W, Zhang J, He J, Zhu F. Distribution of HLA allele frequencies in
399	82 Chinese individuals with coronavirus disease-2019 (COVID-19). HLA. 2020;96:194-
400	6.

401

- 402 19. Warren RL, Birol I. HLA predictions from the bronchoalveolar lavage fluid and blood
- 403 samples of eight COVID-19 patients at the pandemic onset. Bioinformatics. 2020;
- 404 doi:10.1093/bioinformatics/btaa756.

405

- 406 20. Overmyer KA, Shishkova E, Miller IJ, Balnis J, Bernstein MN, Peters-Clarke TM, et
- 407 al. Large-Scale Multi-omic Analysis of COVID-19 Severity. Cell Syst. 2020;
- 408 doi:10.1016/j.cels.2020.10.003.

409

- 410 21. Szolek A, Schubert B, Mohr C, Sturm M, Feldhahn M, Kohlbacher O. OptiType:
- 411 precision HLA typing from next-generation sequencing data. Bioinformatics.

412 2014;30:3310-6.

413

414 22. Boegel S, Löwer M, Schäfer M, Bukur T, de Graaf J, Boisguérin V, et al. HLA typing

415 from RNA-Seq sequence reads. Genome Med. 2012;4:102.

416

- 417 23. Warren RL, Choe G, Freeman DJ, Castellarin M, Munro S, Moore R, Holt RA.
- 418 Derivation of HLA types from shotgun sequence datasets. Genome Med. 2012;4:95.

419

- 420 24. Valenzuela, C. Dos soluciones para la estimación de "odds ratios" con ceros [2
- 421 solutions for estimating odds ratios with zeros]. Rev Med Chil. 1993;121:1441-4.

423 25. Gonzalez-Galarza FF, McCabe A, Santos EJ, Jones J, Takeshita LY, Ortega-Rivera

424 ND, et al. Allele frequency net database (AFND) 2020 update: gold-standard data

425 classification, open access genotype data and new query tools. Nucleic Acid Research.

426 **2020;48:D783-8**.

427

428 26. Allele frequency net database. <u>http://allelefrequencies.net/</u>

429

430 27. Han F, Lin L, Warby SC, Faraco J, Li J, Dong SX, et al. Narcolepsy onset is

431 seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol.

432 2011;70:410-7.

433

434 28. Han F, Faraco J, Dong XS, Ollila HM, Lin L, Li J, et al. Genome wide analysis of

435 narcolepsy in China implicates novel immune loci and reveals changes in association

436 prior to versus after the 2009 H1N1 influenza pandemic. PLoS Genet.

437 **2013;9:e1003880**.

438

439 29. Heier MS, Gautvik KM, Wannag E, Bronder KH, Midtlyng E, Kamaleri Y, Storsaeter

440 J. Incidence of narcolepsy in Norwegian children and adolescents after vaccination

441 against H1N1 influenza A. Sleep Med. 2013;14:867-71.

442

443 30. Moss AJ, Gaughran FP, Karasu A, Gilbert AS, Mann AJ, Gelder CM, et al.

444 Correlation between human leukocyte antigen class II alleles and HAI titers detected

445 post-influenza vaccination. PLoS One. 2013;8:e71376.

447	31. Montplaisir J, Petit D, Quinn MJ, Ouakki M, Deceuninck G, Desautels A, et al. Risk							
448	of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic							
449	influenza vaccine in Quebec. PLoS One. 2014;9:e108489.							
450								
451	32. Wijnans L, Lecomte C, de Vries C, Weibel D, Sammon C, Hviid A, et al. The							
452	incidence of narcolepsy in Europe: before, during, and after the influenza							
453	A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine. 2013;31:1246-54.							
454								
455	33. Aran A, Lin L, Nevsimalova S, Plazzi G, Hong SC, Weiner K, et al. Elevated anti-							
456	streptococcal antibodies in patients with recent narcolepsy onset. Sleep. 2009;32:979-							
457	83.							
458								
459	34. Mahlios J, De la Herrán-Arita AK, Mignot E. The autoimmune basis of narcolepsy.							
460	Curr Opin Neurobiol. 2013;23:767-73.							
461								
462	35. Dutta M, Dutta P, Medhi S, Borkakoty B, Biswas D. Polymorphism of HLA class I							
463	and class II alleles in influenza A(H1N1)pdm09 virus infected population of Assam,							
464	Northeast India. J Med Virol. 2018;90:854-60.							
465								
466	36. Olvera A, Pérez-Álvarez S, Ibarrondo J, Ganoza C, Lama JR, Lucchetti A, et al. The							
467	HLA-C*04: 01/KIR2DS4 gene combination and human leukocyte antigen alleles with							
468	high population frequency drive rate of HIV disease progression. AIDS. 2015;29:507-17.							

- 470 37. Nguyen A, David JK, Maden SK, Wood MA, Weeder BR, Nellore A, Thompson RF.
- 471 Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome
- 472 Coronavirus 2. J Virol. 2020;94:e00510-20.
- 473
- 474 38. Lin M, Tseng HK, Trejaut JA, Lee HL, Loo JH, Chu CC, et al. Association of HLA
- 475 class I with severe acute respiratory syndrome coronavirus infection. BMC Med Genet.
- 476 2003;4:9.
- 477
- 478 39. Sanchez-Mazas A. HLA studies in the context of coronavirus outbreaks. Swiss Med
- 479 Wkly. 2020;150:w20248.

480 **TABLES**

481

- 482 **Table 1**. HLA-I alleles identified in 10% or more COVID-19 positive patients and
- 483 statistical tests of enrichment in the Overmyer *et al.* [20] COVID-19 positive (vs.
- 484 negative) cohort and association with hospitalization. Red font indicates significant
- 485 associations (Fisher's Exact Test) not corrected for multiple hypothesis tests.

HLA-I	COVID+ patients	ICU- patients	ICU+ patients	COVID- patients	H1: Enriched in COVID+ Fisher's Exact Test p-value	H1: Increased risk of hospitalization Fisher's Exact Test p-value
A*02:01	30	15	15	12	0.9614	0.5862
A*24:02	23	12	11	6	0.6161	0.5000
C*07:02	22	9	13	7	0.7890	0.8865
C*07:01	18	6	12	7	0.8991	0.9668
C*04:01	18	4	14	3	0.3231	0.0087
C*06:02	16	8	8	6	0.8708	0.6071
B*51:01	16	6	10	2	0.2292	0.9143
C*03:04	14	4	10	3	0.5171	0.9796
C*15:02	14	6	8	1	0.1363	0.8060
A*01:01	13	5	8	7	0.9742	0.8832
A*03:01	13	7	6	5	0.8680	0.5000
A*30:02	13	7	6	0	0.0417	0.5000
B*07:02	12	5	7	5	0.8969	0.8217
A*30:01	12	8	4	1	0.2016	0.1783
B*44:02	11	4	7	4	0.8320	0.9001
A*68:01	11	5	6	0	0.0697	0.7377
A*11:01	10	1	9	2	0.5320	0.0078

486

487

- 489 **Table 2**. HLA-II alleles identified in 10% or more COVID-19 positive patients and
- 490 statistical tests of enrichment in the Overmyer *et al.* [20] COVID-19 positive (vs.
- 491 negative) cohort and association with hospitalization. Red font indicates significant

HLA-II	COVID+ patients	ICU- patients	ICU+ patients	COVID- patients	H1: Enriched in COVID+ Fisher's Exact Test p-value	H1: Increased risk of hospitalization Fisher's Exact Test p-value
DPA1*01:03	46	21	25	17	0.9812	0.8421
DQA1*01:02	40	26	14	10	0.5363	0.0121
DPB1*04:01	22	9	13	10	0.9726	0.8865
DPA1*02:02	29	16	13	2	0.0174	0.3299
DPA1*02:01	22	11	11	6	0.6578	0.5952
DQA1*05:02	19	9	10	3	0.2824	0.6945
DPB1*01:01	19	10	9	3	0.2824	0.5000
DQB1*06:11	11	6	5	3	0.6811	0.5000
DRB1*13:01	10	7	3	4	0.8689	0.1589
DQB1*06:02	10	6	4	3	0.7348	0.3703
DRB1*15:01	10	4	6	2	0.5320	0.8411

492 associations (Fisher's Exact Test) not corrected for multiple hypothesis tests.

493

494

496 **FIGURES**











Figure 2. HLA alleles – demographics combinations with diagnostic (bottom) or 508 509 prognostic (top) potential in a COVID-19 cohort. We calculated the odds ratio (OR) 510 for each HLA-I and HLA-II alleles observed in 10% or more of patients, and plotted OR 511 and the influence of demographics for HLA alleles showing significant associations 512 (from **Tables 1 and 2**). First, looking at the influence of demographic characteristics 513 such as sex (male/female), age (65 years old or above/less than 65 years old) and 514 ethnicity (minority/white ethnic background) on the susceptibility of patients with these 515 alleles to test positive for COVID-19 (lower two panels), and on the risk associated with 516 ICU hospitalization (upper three panels). Red asterisks indicate significant demographic 517 characteristics (Fisher's Exact Test) not corrected for multiple hypothesis tests.